Compare National Beverage Corp. (FIZZ) vs Tempus AI (TEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Tempus AI — how do they compare? National Beverage Corp. trades at $30.88 (market cap $2.77B), while Tempus AI trades at $70.55 (market cap $12.77B). The key difference: Tempus AI is far larger — about 4.6× National Beverage Corp.'s market cap, and Tempus AI is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and Tempus AI for 22 Days on average.
| FIZZ | TEM | |
|---|---|---|
Market Cap | $2.77B | $12.77B |
Volume | 413,496 | 8,980,490 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $37.73 | $99.28 |
52-Week Low | $29.20 | $41.55 |
Typical Hold Time | 33 Days | 22 Days |
Enterprise Value | $2.72B | $13.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $29.60, down 1.4% with bearish technical signals from moving averages. The company reported flat revenue of $1.2B in 2025 but maintained strong profitability with 36.2% gross margins and 40.1% ROE. Recent Q1 2027 results showed the first year-over-year revenue growth since Q1 2026, though margins compressed to 35% and EPS declined to $0.50. Analyst sentiment is cautious with 50% sell ratings amid concerns about stalled growth and margin pressure from input costs.
The outlook remains challenging with LaCroix volumes declining for four consecutive years and Trump tariffs impacting profitability. While valuation multiples appear reasonable (P/E 15.9, EV/EBITDA 11.3), the lack of clear growth catalysts and negative cash flow trends present headwinds. The $3.25 special dividend provides shareholder return but reduces equity base, highlighting the company's mature market position.
Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite negative profitability. Recent FDA clearance for its ECG-MR AI product and 13 abstracts accepted for ESMO Congress 2026 highlight ongoing innovation. Revenue grew to $1.4B in 2026, though net losses persist. The stock shows strong analyst support with a $72.60 consensus target and 64% buy ratings.
Outlook remains cautiously optimistic driven by AI healthcare adoption and data licensing growth, but high valuation multiples and sustained losses pose risks. Investor sentiment is positive amid recent insider selling and institutional interest, yet profitability challenges and competitive pressures require monitoring for long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →
